{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-telemedicine-visits-and-remote-ae-reporting”
},
“headline”: “SOP for Telemedicine Visits and Remote AE Reporting”,
“description”: “This SOP describes standardized procedures for conducting telemedicine visits and remote adverse event (AE) reporting in clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements while protecting subject privacy and data integrity.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Telemedicine Visits and Remote AE Reporting

Purpose

The purpose of this SOP is to define standardized procedures for implementing telemedicine visits and remote adverse event (AE) reporting in clinical trials. It enables subject safety, data integrity, and regulatory compliance while facilitating decentralized and hybrid trial designs.

Scope

This SOP applies to sponsors, investigators, site staff, CROs, and regulatory teams involved in clinical trials using telemedicine and remote AE reporting solutions. It covers teleconsultation procedures, remote AE identification, documentation, reporting, privacy safeguards, and inspection readiness.

Responsibilities

• Sponsor: Ensures validated telemedicine platforms and oversees remote AE reporting compliance.
• Investigator: Conducts teleconsultations, assesses AEs, and ensures accurate documentation.
• Site Staff: Support telemedicine visits and assist subjects in AE reporting.
• CRO: Monitors telemedicine compliance and audits remote AE documentation.
• QA: Audits telemedicine and AE reporting systems for compliance.
• EC/IRB: Reviews and approves telemedicine procedures and AE reporting processes.

Accountability

The Principal Investigator is accountable for the conduct of telemedicine visits and AE reporting accuracy. The Sponsor is accountable for overall oversight and compliance with global regulations.

Procedure

1. Platform Validation
1.1 Use telemedicine platforms validated for security, privacy, and data retention.
1.2 Ensure compliance with HIPAA, GDPR, and FDA Part 11.
1.3 Document validation in Telemedicine Platform Log (Annexure-1).

2. Telemedicine Visits
2.1 Schedule visits according to protocol timelines.
2.2 Obtain subject consent for teleconsultation.
2.3 Conduct visits via secure video/audio systems.
2.4 Document visit details in Telemedicine Visit Log (Annexure-2).

3. Remote AE Identification
3.1 Instruct subjects to report AEs via phone, email, or telemedicine platform.
3.2 Investigators review and classify AE severity and causality.
3.3 Document in Remote AE Log (Annexure-3).

4. AE Documentation and Reporting
4.1 Record AE details in eCRF within 24 hours of identification.
4.2 Report SAEs to sponsor within regulatory timelines.
4.3 Maintain AE Notification Log (Annexure-4).

5. Data Privacy
5.1 Ensure encrypted communication and secure storage.
5.2 Maintain confidentiality per GDPR/HIPAA.
5.3 Document in Data Privacy Log (Annexure-5).

6. Training
6.1 Train investigators and staff in telemedicine workflows.
6.2 Provide subjects with instructions for reporting AEs remotely.
6.3 Record in Training Log (Annexure-6).

7. Inspection Readiness
7.1 Maintain inspection-ready telemedicine and AE reporting records.
7.2 Document mock inspections in Inspection Readiness Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• AE: Adverse Event
• SAE: Serious Adverse Event
• CRO: Contract Research Organization
• QA: Quality Assurance
• EC/IRB: Ethics Committee/Institutional Review Board
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act
• TMF: Trial Master File
• ISF: Investigator Site File
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization

Documents

1. Telemedicine Platform Log (Annexure-1)
2. Telemedicine Visit Log (Annexure-2)
3. Remote AE Log (Annexure-3)
4. AE Notification Log (Annexure-4)
5. Data Privacy Log (Annexure-5)
6. Training Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)

References

• FDA – Guidance on Remote Monitoring and Telemedicine
• EMA – Telemedicine in Clinical Trials
• CDSCO – Telemedicine Trial Rules
• ICH GCP – Adverse Event Reporting Standards
• WHO – Telemedicine and Remote AE Guidance

Version: 1.0

Approval Section

Annexures

Annexure-1: Telemedicine Platform Log

Annexure-2: Telemedicine Visit Log

Annexure-3: Remote AE Log

Annexure-4: AE Notification Log

Annexure-5: Data Privacy Log

Annexure-6: Training Log

Annexure-7: Inspection Readiness Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-remote-central-sdv-for-decentralized-trials”
},
“headline”: “SOP for Remote/Central SDV for Decentralized Trials”,
“description”: “This SOP defines standardized procedures for remote and central source data verification (SDV) in decentralized clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP, covering secure data access, monitoring, audit trails, privacy, and inspection readiness.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Remote/Central SDV for Decentralized Trials

Purpose

The purpose of this SOP is to establish standardized procedures for remote and central source data verification (SDV) in decentralized clinical trials. Remote/central SDV ensures data quality, regulatory compliance, and subject safety while reducing the need for onsite monitoring.

Scope

This SOP applies to sponsors, CROs, investigators, monitors, data managers, and QA staff involved in decentralized clinical trials. It covers processes for remote access to source data, central monitoring workflows, data verification, audit trails, and regulatory inspection readiness.

Responsibilities

• Sponsor: Provides oversight, ensures technology compliance, and approves monitoring plans.
• Investigator: Grants secure access to source data and ensures subject confidentiality.
• Monitor: Conducts remote SDV and documents findings in monitoring reports.
• CRO: Manages monitoring platforms and coordinates with sites.
• QA: Audits remote SDV processes and ensures compliance with regulations.

Accountability

The Sponsor’s Clinical Data Management Head is accountable for remote and central SDV oversight. Investigators are accountable for ensuring data accuracy and access compliance at site level.

Procedure

1. Planning and Preparation
1.1 Develop a monitoring plan specifying remote and central SDV procedures.
1.2 Document in Remote Monitoring Plan Log (Annexure-1).

2. Secure Data Access
2.1 Provide authorized monitors with role-based secure access to EHRs and eSource systems.
2.2 Maintain access details in Secure Access Log (Annexure-2).

3. Source Data Verification (SDV)
3.1 Verify subject-level data (e.g., demographics, visit dates, lab results) remotely.
3.2 Document findings in Remote SDV Log (Annexure-3).

4. Central Monitoring
4.1 Conduct data trend analysis across multiple sites.
4.2 Identify outliers or protocol deviations.
4.3 Document in Central Monitoring Log (Annexure-4).

5. Data Privacy and Confidentiality
5.1 Comply with GDPR, HIPAA, and local data protection rules.
5.2 Mask identifiers where possible.
5.3 Maintain entries in Data Privacy Compliance Log (Annexure-5).

6. Audit Trail and Documentation
6.1 Maintain audit trails of all remote access and SDV activities.
6.2 Record in Audit Trail Log (Annexure-6).

7. Reporting
7.1 Generate remote monitoring reports within 10 working days of activity.
7.2 File in TMF and ISF.

8. Inspection Readiness
8.1 Ensure all SDV records are inspection-ready.
8.2 Document inspection simulations in Inspection Readiness Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• SDV: Source Data Verification
• CRO: Contract Research Organization
• QA: Quality Assurance
• EHR: Electronic Health Record
• TMF: Trial Master File
• ISF: Investigator Site File
• GCP: Good Clinical Practice
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act
• FDA: Food and Drug Administration
• EMA: European Medicines Agency
• CDSCO: Central Drugs Standard Control Organization

Documents

1. Remote Monitoring Plan Log (Annexure-1)
2. Secure Access Log (Annexure-2)
3. Remote SDV Log (Annexure-3)
4. Central Monitoring Log (Annexure-4)
5. Data Privacy Compliance Log (Annexure-5)
6. Audit Trail Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)

References

• FDA – Guidance on Remote Monitoring
• EMA – Remote Monitoring Guidance
• CDSCO – Remote SDV in Decentralized Trials
• ICH GCP – Data Monitoring and Verification
• WHO – Decentralized Trials Monitoring

Version: 1.0

Approval Section

Annexures

Annexure-1: Remote Monitoring Plan Log

Annexure-2: Secure Access Log

Annexure-3: Remote SDV Log

Annexure-4: Central Monitoring Log

Annexure-5: Data Privacy Compliance Log

Annexure-6: Audit Trail Log

Annexure-7: Inspection Readiness Log

Revision History

For more SOPs visit: Pharma SOP